Regulation of foam cells by adenosine

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 32, Issue 4, 2012, Pages 879-886

  Reiss, Allison B ^a   Cronstein, Bruce N ^b  

^a WINTHROP UNIVERSITY HOSPITAL   (United States)

^b NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

ABC transporter; adenosine receptor; foam cells; macrophages

Indexed keywords

ABC TRANSPORTER A1; ABC TRANSPORTER G1; ADENOSINE; ADENOSINE A1 RECEPTOR; ADENOSINE A2 RECEPTOR; ADENOSINE A3 RECEPTOR; APOLIPOPROTEIN E; CHOLESTEROL 27 HYDROXYLASE; CYCLOOXYGENASE 1 INHIBITOR; CYCLOOXYGENASE 2 INHIBITOR; CYTOCHROME P450; G PROTEIN COUPLED RECEPTOR; HYPOXIA INDUCIBLE FACTOR 1; LIVER X RECEPTOR ALPHA; LIVER X RECEPTOR BETA; LOW DENSITY LIPOPROTEIN; METHOTREXATE; OXIDIZED LOW DENSITY LIPOPROTEIN RECEPTOR 1; UNCLASSIFIED DRUG;

ARTICLE; ATHEROGENESIS; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; CELL TRANSPORT; CHOLESTEROL TRANSPORT; FOAM CELL; HUMAN; INTRACELLULAR SIGNALING; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REGULATORY MECHANISM;

ADENOSINE; ADENOSINE A2 RECEPTOR AGONISTS; ANIMALS; ATHEROSCLEROSIS; CHOLESTEROL; CYCLOOXYGENASE INHIBITORS; FOAM CELLS; HOMEOSTASIS; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1; INFLAMMATION; RECEPTORS, PURINERGIC P1; SCAVENGER RECEPTORS, CLASS E; SIGNAL TRANSDUCTION;

EID: 84858675634     PISSN: 10795642     EISSN: 15244636     Source Type: Journal    
DOI: 10.1161/ATVBAHA.111.226878     Document Type: Article

References (96)

1. Delyani JA, Van Wylen DGL. Endocardial and epicardial interstitial purines and lactate during graded ischemia. Am J Physiol. 1994;266: H1019-H1026. (Pubitemid 24121321)
2. McIntosh VJ, Lasley RD. Adenosine receptor-mediated cardioprotection: are all 4 subtypes required or redundant? J Cardiovasc Pharmacol Ther. 2011 [Epub ahead of print].
3. Hasko G, Linden J, Cronstein B, Pacher P. Adenosine receptors: therapeutic aspects for inflammatory and immune diseases. Nat Rev Drug Discov. 2008;7:759-770.
4. Barnholt KE, Kota RS, Aung HH, Rutledge JC. Adenosine blocks IFN-α-induced phosphorylation of STAT1 on serine 727 to reduce macrophage activation. J Immunol. 2009;183:6767-6777.
5. Leon ML, Zuckerman SH. Gamma interferon: a central mediator in atherosclerosis. Inflamm Res. 2005;54:395-411. (Pubitemid 41609377)
6. Reiss AB, Hammerschlag MR, Awadallah NW, Roblin PM, Chan ESL, Cronstein BN. Immune modulation of cholesterol homeostasis. Recent Res Dev Protein Eng. 2001;1:21-38.
7. Fox AC, Reed GE, Meilman H, Silk BB. Release of nucleosides from canine and human hearts as an index of prior ischemia. Am J Cardiol. 1979;43:52-58. (Pubitemid 9108987)
8. Berne RM, Belardinelli L. Effects of hypoxia and ischaemia on coronary vascular resistance, A-V node conduction and S-A node excitation. Acta Med Scand Suppl. 1985;694:9-19. (Pubitemid 15025746)
9. Miller WL, Thomas RA, Berne RM, Rubio R. Adenosine production in the ischemic kidney. Circ Res. 1978;43:390-397. (Pubitemid 9019764)
10. Jacobson KA, Gao ZG. Adenosine receptors as therapeutic targets. Nat Rev Drug Discov. 2006;5:247-264. (Pubitemid 43336037)
11. Hasko G, Cronstein BN. Adenosine: an endogenous regulator of innate immunity. Trends Immunol. 2004;25:33-39. (Pubitemid 38032805)
12. Ross R. Atherosclerosis: an inflammatory disease. N Engl J Med. 1999; 340:115-126.
13. Glass CK, Witztum JL. Atherosclerosis: the road ahead. Cell. 2001;104: 503-516. (Pubitemid 32201946)
14. Reiss AB, Glass AD. Atherosclerosis: immune and inflammatory aspects. J Investig Med. 2006;54:123-131.
15. Pennings M, Meurs I, Ye D, Out R, Hoekstra M, Van Berkel TJ, Van Eck M. Regulation of cholesterol homeostasis in macrophages and consequences for atherosclerotic lesion development. FEBS Lett. 2006;580: 5588-5596. (Pubitemid 44465904)
16. Stary HC, Chandler AB, Glagov S, Guyton JR, Insull W Jr, Rosenfeld ME, Schaffer SA, Schwartz CJ, Wagner WD, Wissler RW. A definition of initial, fatty streak, and intermediate lesions of atherosclerosis: a report from the Committee on Vascular Lesions of the Council on Arteriosclerosis, American Heart Association. Circulation. 1994;89:2462-2478. (Pubitemid 24142837)
17. Kolodgie FD, Virmani R, Burke AP, Farb A, Weber DK, Kutys R, Finn AV, Gold HK. Pathologic assessment of the vulnerable human coronary plaque. Heart. 2004;90:1385-1391. (Pubitemid 39626306)
18. Stephen SL, Freestone K, Dunn S, Twigg MW, Homer-Vanniasinkam S, Walker JH, Wheatcroft SB, Ponnambalam S. Scavenger receptors and their potential as therapeutic targets in the treatment of cardiovascular disease. Int J Hypertens. 2010;2010:646929.
19. van der Velde AE. Reverse cholesterol transport: from classical view to new insights. World J Gastroenterol. 2010;16:5908-5915.
20. Im SS, Osborne TF. Liver x receptors in atherosclerosis and inflammation. Circ Res. 2011;108:996-1001.
21. Voloshyna I, Reiss AB. The ABC transporters in lipid flux and atherosclerosis. Prog Lipid Res. 2011;50:213-224.
22. Reiss AB, Awadallah NW, Cronstein BN. Cytochrome P450 cholesterol 27-hydroxylase: an anti-atherogenic enzyme. Rec Res Dev Lipid Res. 2000;4:39-50.
23. Silverstein RL, Febbraio M. CD36 and atherosclerosis. Curr Opin Lipidol. 2000;11:483-491.
24. Dhaliwal BS, Steinbrecher UP. Scavenger receptors and oxidized low density lipoproteins, Clin Chim Acta. 1999;286:191-205. (Pubitemid 29406108)
25. Suzuki H, Kurihara Y, Takeya M, Kamada N, Kataoka M, Jishage K, Ueda O, Sakaguchi H, Higashi T, Suzuki T, Takashima Y, Kawabe Y, Cynshi O, Wada Y, Honda M, Kurihara H, Aburatani H, Doi T, Matsumoto A, Azuma S, Noda T, Toyoda Y, Itakura H, Yazaki Y, Horiuchi S, Takahashi K, Kruijt JK, van Berkel TJC, Steinbrecher UP, Ishibashi S, Maeda N, Gordon S, Kodama T. A role for macrophage scavenger receptors in atherosclerosis and susceptibility to infection. Nature. 1997;386:292-296. (Pubitemid 27142516)
26. Mäkinen PI, Lappalainen JP, Heinonen SE, Leppänen P, Lähteenvuo MT, Aarnio JV, Heikkilä J, Turunen MP, Ylä-Herttuala S. Silencing of either SR-A or CD36 reduces atherosclerosis in hyperlipidaemic mice and reveals reciprocal upregulation of these receptors. Cardiovasc Res. 2010; 88:530-538.
27. Dzeletovic S, Breuer O, Lund E, Diczfalusy U. Determination of cholesterol oxidation products in human plasma by isotope dilution-mass spectrometry. Anal Biochem. 1995;225:73-80.
28. Babiker A, Andersson O, Lund E, Xiu R, Deeb S, Reshef A, Leitersdorf E, Diczfalusy U, Bjorkhem I. Elimination of cholesterol in macrophages and endothelial cells by the sterol 27-hydroxylase mechanism. J Biol Chem. 1997;272:26253-26261.
29. Schroepfer GJ Jr. Oxysterols: modulators of cholesterol metabolism and other processes. Physiol Rev. 2000;80:361-554. (Pubitemid 30060568)
30. Lawn RM, Wade DP, Garvin MR, Wang X, Schwartz K, Porter JG, Seilhamer JJ, Vaughan AM, Oram JF. The Tangier disease gene product ABC1 controls the cellular apolipoprotein-mediated lipid removal pathway. J Clin Invest. 1999;104:R25-R31. (Pubitemid 29536327)
31. Oram JF, Vaughan AM. ATP-binding cassette cholesterol transporters and cardiovascular disease. Circ Res. 2006;99:1031-1043. (Pubitemid 44729927)
32. Wade DP, Owen JS. Regulation of the cholesterol efflux gene, ABCA1 Lancet. 2001;357:161-163.
33. Aiello RJ, Brees D, Bourassa PA, Royer L, Lindsey S, Coskran T, Haghpassand M, Francone OL. Increased atherosclerosis in hyperlipidemic mice with inactivation of ABCA1 in macrophages. Arterioscler Thromb Vasc Biol. 2002;22:630-637. (Pubitemid 34408745)
34. Van Eck M, Bos IS, Kaminski WE, Orsó E, Rothe G, Twisk J, Böttcher A, Van Amersfoort ES, Christiansen-Weber TA, Fung-Leung WP, Van Berkel TJ, Schmitz G. Leukocyte ABCA1 controls susceptibility to atherosclerosis and macrophage recruitment into tissues. Proc Natl Acad Sci USA. 2002;99:6298-6303. (Pubitemid 34493306)
35. Venkateswaran A, Lafitte BA, Joseph SB, Mak PA, Wilpitz DC, Edwards PA, Tontonoz P. Control of cellular cholesterol efflux by the nuclear oxysterol receptor LXR. Proc Natl Acad Sci USA. 2000;97: 12097-12102.
36. Fu X, Menke JG, Chen Y, Zhou G, MacNaul KL, Wright SD, Sparrow CP, Lund EG. 27-Hydroxycholesterol is an endogenous ligand for LXR in cholesterol-loaded cells. J Biol Chem. 2001;276:38378-38387.
37. Zelcer N, Tontonoz P. Liver X receptors as integrators of metabolic and inflammatory signaling. J Clin Invest. 2006;116:607-614. (Pubitemid 43326865)
38. Janowski BA, Grogan MJ, Jones SA, Wisely GB, Kliewer SA, Corey EJ, Mangelsdorf DJ. Structural requirements of ligands for the oxysterol liver X receptors LXR and LXR. Proc Natl Acad Sci USA. 1999;96: 266-271. (Pubitemid 29036088)
39. Cronstein BN. Low-dose methotrexate: a mainstay in the treatment of rheumatoid arthritis. Pharmacol Rev. 2005;57:163-172. (Pubitemid 41043882)
40. Gonzalez-Gay MA, Gonzalez-Juanatey C, Martin J. Rheumatoid arthritis: a disease associated with accelerated atherogenesis. Semin Arthritis Rheum. 2005;35:8-17. (Pubitemid 41111466)
41. Choi HK, Hernan MA, Seeger JD, Robins JM, Wolfe F. Methotrexate and mortality in patients with rheumatoid arthritis: a prospective study. Lancet. 2002;359:1173-1177. (Pubitemid 34304256)
42. Cronstein BN, Naime D, Ostad E. The antiinflammatory effects of methotrexate are mediated by adenosine. Adv Exp Med Biol. 1994;370: 411-416.
43. Hasko G, Pacher P, Deitch EA, Vizi ES. Shaping of monocyte and macrophage function by adenosine receptors. Pharmacol Ther. 2007;113: 264-275. (Pubitemid 46149045)
44. McPherson JA, Barringhaus KG, Bishop GG, Sanders JM, Rieger JM, Hesselbacher SE, Gimple LW, Powers ER, Macdonald T, Sullivan G, Linden J, Sarembock IJ. Adenosine A(2A) receptor stimulation reduces inflammation and neointimal growth in a murine carotid ligation model. Arterioscler Thromb Vasc Biol. 2001;21:791-796. (Pubitemid 32448770)
45. Reiss AB, Rahman MM, Chan ESL, Montesinos MC, Awadallah NW, Cronstein BN. Adenosine A2A receptor occupancy stimulates expression of proteins involved in reverse cholesterol transport and inhibits foam cell formation in macrophages. J Leukoc Biol. 2004;76:727-734. (Pubitemid 39129107)
46. Tedgui A, Mallat Z. Cytokines in atherosclerosis: pathogenic and regulatory pathways. Physiol Rev. 2006;86:515-581.
47. Larigauderie GF, Christophe JM, Lasselin C, Copin C, Fruchart J-C, Castro G, Rouis M. Adipophilin enhances lipid accumulation and prevents lipid efflux from THP-1 macrophages. Arterioscler Thromb Vasc Biol. 2004;24:504-510. (Pubitemid 38326145)
48. Fach EM, Garulacan LA, Gao J, Xiao Q, Storm SM, Dubaquie YP, Hefta SA, Opiteck GJ. In vitro biomarker discovery for atherosclerosis by proteomics. Mol Cell Proteomics. 2004;3:1200-1210.
49. Khoa ND, Montesinos MC, Reiss AB, Delano D, Awadallah N, Cronstein BN. Inflammatory cytokines regulate function and expression of adenosine A(2A) receptors in human monocytic THP-1 cells. J Immunol. 2001;16:4026-4032. (Pubitemid 32910848)
50. Bshesh K, Zhao B, Spight D, Biaggioni I, Feokistov I, Denenberg A, Wong HR, Shanley TP. The A2A receptor mediates an endogenous regulatory pathway of cytokine expression in THP-1 cells. J Leukoc Biol. 2002;72:1027-1036. (Pubitemid 35365178)
51. Bingham TC, Cronstein BN, Fisher EA, Parathath S, Reiss A, Chan E. A2A adenosine receptor stimulation decreases foam cell formation by enhancing ABCA1-dependent cholesterol efflux. J Leukoc Biol. 2010;87: 683-690.
52. Reiss AB, Carsons SE, Anwar K, Rao S, Edelman SD, Zhang H, Fernandez P, Cronstein BN, Chan ES. Atheroprotective effects of methotrexate on reverse cholesterol transport proteins and foam cell transformation in human THP-1 monocyte/macrophages. Arthritis Rheum. 2008; 58:3675-3683.
53. Coomes E, Chan ES, Reiss AB. Methotrexate in atherogenesis and cholesterol metabolism. Cholesterol. 2011;2011:503028.
54. Deanfield JE, Halcox JP, Rabelink TJ. Endothelial function and dysfunction: testing and clinical relevance. Circulation. 2007;115: 1285-1295. (Pubitemid 46594773)
55. Kataoka H, Kume N, Miyamoto S, Minami M, Moriwaki H, Murase T, Sawamura T, Masaki T, Hashimoto N, Kita T. Expression of lectinlike oxidized low-density lipoprotein receptor-1 in human atherosclerotic lesions. Circulation. 1999;99:3110-3117. (Pubitemid 29289075)
56. Mehta JL, Chen J, Hermonat PL, Romeo F, Novelli G. Lectin-like, oxidized low-density lipoprotein receptor-1 (LOX-1): a critical player in the development of atherosclerosis and related disorders. Cardiovasc Res. 2006;69:36-45. (Pubitemid 41814809)
57. Mehta JL, Li DY. Identification and autoregulation of receptors for Ox-LDL in cultured human coronary artery endothelial cells. Biochem Biophys Res Commun. 1998;248:511-514. (Pubitemid 28404451)
58. Kume N, Moriwaki H, Kataoka H, Minami M, Murase T, Sawamura T, Masaki T, Kita T. Inducible expression of LOX-1, a novel receptor for oxidized LDL, in macrophages and vascular smooth muscle cells. Ann N Y Acad Sci. 2000;902:323-327. (Pubitemid 30389142)
59. Kataoka H, Kume N, Miyamoto S. Oxidized LDL modulates Bax/Bcl-2 through the lectin-like Ox-LDL receptor-1 in vascular smooth muscle cells. Arterioscler Thromb Vasc Biol. 2001;21:955-960. (Pubitemid 34168652)
60. Reiss AB, Anwar K, Wirkowski P. Lectin-like oxidized low density lipoprotein receptor 1 (LOX-1) in atherogenesis: a brief review. Curr Med Chem. 2009;16:2641-2652.
61. Sawamura T, Kume N, Aoyama T, Moriwaki H, Hoshikawa H, Aiba Y, Tanaka T, Miwa S, Katsura Y, Kita T, Masaki T. An endothelial receptor for oxidized low-density lipoprotein. Nature. 1997;386:73-77. (Pubitemid 27130922)
62. Ishino S, Mukai T, Kume N, Asano D, Ogawa M, Kuge Y, Minami M, Kita T, Shiomi M, Saji H. Lectin-like oxidized LDL receptor-1 (LOX-1) expression is associated with atherosclerotic plaque instability: analysis in hypercholesterolemic rabbits. Atherosclerosis. 2007;195:48-56. (Pubitemid 47561943)
63. Chen CH, Jiang W, Via DP, Luo S, Li TR, Lee YT, Henry PD. Oxidized low-density lipoproteins inhibit endothelial cell proliferation by suppressing basic fibroblast growth factor expression. Circulation. 2000;101: 171-177. (Pubitemid 30044257)
64. Dunn S, Vohra RS, Murphy JE, Homer-Vanniasinkam S, Walker JH, Ponnambalam S. The lectin-like oxidized low-density-lipoprotein receptor: a pro-inflammatory factor in vascular disease. Biochem J. 2008;409: 349-355. (Pubitemid 351184953)
65. Kume N, Sawamura T, Moriwaki H, Itokawa S, Hoshikawa H, Aoyama A, Nishi E, Ueno Y, Masaki T, Kita T. Inducible expression of LOX-1, a novel lectin-like receptor for oxidized low density lipoprotein, in vascular endothelial cells. Circ Res. 1998;83:322-327. (Pubitemid 28371322)
66. Pirillo A, Reduzzi A, Ferri N, Kuhn H, Corsini A, Catapano AL. Upregulation of lectine-like oxidized low-density lipoprotein receptor-1 (LOX-1) by 15-lipoxygenase-modified LDL in endothelial cells. Atherosclerosis. 2011;214:331-337.
67. Wang GL, Semenza GL. Purification and characterization of hypoxiainducible factor 1. J Biol Chem. 1995;270:1230-1237.
68. Nishi K, Oda T, Takabuchi S, Oda S, Fukuda K, Adachi T, Semenza GL, Shingu K, Hirota K. LPS induces hypoxia-inducible factor 1 activation in macrophage-differentiated cells in a reactive oxygen species-dependent manner. Antioxid Redox Signal. 2008;10:983-995. (Pubitemid 351301367)
69. Sluimer JC, Gasc JM, van Wanroij JL, Kisters N, Groeneweg M, Sollewijn Gelpke MD, Cleutjens JP, van den Akker LH, Corvol P, Wouters BG, Daemen MJ, Bijnens AP. Hypoxia, hypoxia-inducible transcription factor, and macrophages in human atherosclerotic plaques are correlated with intraplaque angiogenesis. J Am Coll Cardiol. 2008;51: 1258-1265. (Pubitemid 351400903)
70. Jiang G, Li T, Qiu Y, Rui Y, Chen W, Lou Y. RNA interference for HIF-1-inhibits foam cells formation in vitro. Eur J Pharmacol. 2007; 562:183-190.
71. De Ponti C, Carini R, Alchera E, Nitti MP, Locati M, Albano E, Cairo G, Tacchini L. Adenosine A2a receptor-mediated, normoxic induction of HIF-1 through PKC and PI-3K-dependent pathways in macrophages. J Leukoc Biol. 2007;82:392-402. (Pubitemid 47230651)
72. Gessi S, Fogli E, Sacchetto V, Merighi S, Varani K, Preti D, Leung E, Maclennan S, Borea PA. Adenosine modulates HIF-1β, VEGF, IL-8, and foam cell formation in a human model of hypoxic foam cells. Arterioscler Thromb Vasc Biol. 2010;30:90-97.
73. Patrono C, Roca B. Nonsteroidal antiinflammatory drugs: past, present and future. Pharmacol Res. 2009;59:285-289.
74. Reiss AB, Anwar F, Chan ESL, Anwar K. Disruption of cholesterol efflux by coxib medications and inflammatory processes: link to increased cardiovascular risk. J Invest Med. 2009;57:695-702.
75. Anwar K, Voloshyna I, Littlefield MJ, Carsons SE, Wirkowski PA, Jaber NL, Sohn A, Eapen S, Reiss AB. COX-2 inhibition and inhibition of cytosolic phospholipase A2 increase CD36 expression and foam cell formation in THP-1 cells. Lipids. 2011;46:131-142.
76. Chan ESL, Zhang H, Fernandez P, Edelman SD, Pillinger MH, Ragolia L, Palaia T, Carsons SE, Reiss AB. Effect of COX inhibition on cholesterol efflux proteins and atheromatous foam cell transformation in THP-1 human macrophages: a possible mechanism for increased cardiovascular risk. Arthritis Res Ther. 2007;9:R4.
77. Clark AN, Youkey R, Liu X, Jia L, Blatt R, Day YJ, Sullivan GW, Linden J, Tucker AL. A1 Adenosine receptor activation promotes angiogenesis and release of VEGF from monocytes. Circ Res. 2007;101:1130-1138. (Pubitemid 350146439)
78. Auchampach A. Adenosine receptors and angiogenesis. Circ Res. 2007; 101:1075-1077.
79. Desai A, Victor-Vega C, Gadangi S, Montesinos MC, Chu CC, Cronstein BN. Adenosine A2A receptor stimulation increases angiogenesis by down-regulating production of the antiangiogenic matrix protein thrombospondin. Mol Pharmacol. 2005;67:1406-1413. (Pubitemid 40594139)
80. Belardinelli L, Shryock JC, Snowdy S, Zhang Y, Monopoli A, Lozza G, Ongini E, Olsson RA, Dennis DM. The A2A adenosine receptor mediates coronary vasodilation. J Pharmacol Exp Ther. 1998;284:1066-1073. (Pubitemid 28130836)
81. Teng B, Ledent C, Mustafa SJ. Up-regulation of A2B adenosine receptor in A2A adenosine receptor knockout mouse coronary artery. J Mol Cell Cardiol. 2008;44:905-914.
82. Berwick ZC, Payne GA, Lynch B, Dick GM, Sturek M, Tune JD. Contribution of adenosine A(2A) and A(2B) receptors to ischemic coronary dilation: role of K(V) and K(ATP) channels. Microcirculation. 2010;17:600-607.
83. Olah ME, Caldwell CC. Adenosine receptors and mammalian toll-like receptors: synergism in macrophages. Mol Interv. 2003;370-374.
84. Ohta A, Gorelik E, Prasad SJ, Ronchese F, Lukashev D, Wong MK, Huang X, Caldwell S, Liu K, Smith P, Chen JF, Jackson EK, Apasov S, Abrams S, Sitkovsky M. A2A adenosine receptor protects tumors from antitumor T cells. Proc Natl Acad Sci USA. 2006;103:13132-13137. (Pubitemid 44338928)
85. Yang D, Zhang Y, Nguyen HG, Koupenova M. Chauhan AK., Makitalo M., Jones MR, St Hilaire C, Seldin DC, Toselli P, Lamperti E, Schreiber BM, Gavras H, Wagner DD, Ravid K. The A2B adenosine receptor protects against inflammation and excessive vascular adhesion. J Clin Invest. 2006;116:1913-1923. (Pubitemid 44033315)
86. Von Lubitz DK, Lin RC, Jacobson KA. Cerebral ischemia in gerbils: effects of acute and chronic treatment with adenosine A2A receptor agonist and antagonist. Eur J Pharmacol. 1995;287:295-302. (Pubitemid 26006341)
87. Monopoli A, Lozza G, Forlani A, Mattavelli A, Ongini E. Blockade of adenosine A2A receptors by SCH 58261 results in neuroprotective effects in cerebral ischaemia in rats. Neuroreport. 1998;9:3955-3959. (Pubitemid 29189333)
88. Cunha RA. Neuroprotection by adenosine in the brain: from A(1) receptor activation to A (2A) receptor blockade. Purinergic Signal. 2005;1: 111-134. (Pubitemid 40466898)
89. Peart J, Headrick JP. Intrinsic A1 adenosine receptor activation during ischemia or reperfusion improves recovery in mouse hearts. Am J Physiol Heart Circ Physiol. 2000;279:H2166-H2175.
90. Kin H, Zatta AJ, Lofye MT, Amerson BS, Halkos ME, Kerendi F, Zhao ZQ, Guyton RA, Headrick JP, Vinten-Johansen J. Postconditioning reduces infarct size via adenosine receptor activation by endogenous adenosine. Cardiovasc Res. 2005;67:124-133. (Pubitemid 40798299)
91. Mahaffey KW, Puma JA, Barbagelata NA, DiCarli MF, Leesar MA, Browne KF, Eisenberg PR, Bolli R, Casas AC, Molina-Viamonte V, Orlandi C, Blevins R, Gibbons RJ, Califf RM, Granger CB. Adenosine as an adjunct to thrombolytic therapy for acute myocardial infarction: results of a multicenter, randomized, placebo-controlled trial: the Acute Myocardial Infarction STudy of ADenosine (AMISTAD) trial. J Am Coll Cardiol. 1999;34:1711-1720.
92. Wang H, Zhang W, Zhu C, Bucher C, Blazar BR, Zhang C, Chen JF, Linden J, Wu C, Huo Y. Inactivation of the adenosine A2A receptor protects apolipoprotein E-deficient mice from atherosclerosis. Arterioscler Thromb Vasc Biol. 2009;29:1046-1052.
93. Ross R. The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature. 1993;362:801-809. (Pubitemid 23132154)
94. Lopes LV, Cunha RA, Ribeiro JA. Cross talk between A1 and A2A adenosine receptors in the hippocampus and cortex of young adult and old rats. J Neurophysiol. 1999;82:3196-3203. (Pubitemid 30017446)
95. Norton GR, Woodiwiss AJ, McGinn RJ, Lorbar M, Chung ES, Honeyman TW, Fenton RA, Dobson JG Jr, Meyer TE. Adenosine A1 receptor-mediated anti-adrenergic effects are modulated by A2a receptor activation in rat heart. Am J Physiol Heart Circ Physiol. 1999;276: H341-H349. (Pubitemid 29100599)
96. Tikh EI, Fenton RA, Dobson JG Jr. Contractile effects of adenosine A1 and A2A receptors in the isolated murine heart. Am J Physiol Heart Circ Physiol. 2006;290:H348-H356.